Deloitte have recently released their top five winners in its 2017 Technology Fast 500 list. Two biopharmaceutical companies feature in the top 10, both which have displayed technological innovation, entrepreneurship and rapid growth throughout the year.
Located in the US, we take a brief look at the two companies.
1. Aratana Therapeutics Inc: Leawood, Kansas
Approved by the FDA in 2016, with $100mn invested in innovating pet therapies for six years, Aratana Therapeutics has become a leader in the development, licensing and commercialising of therapeutics for common domestic pets since 2010.
Focusing in areas of pain, inappetence, cancer, viral diseases and allergies, the company’s recent third quarter figures highlight a total net revenue of $6.2mn and a net loss of $8.9mn. However, the launch of three products, Nocita, Galliprant and Entyce will enable it to further develop partnerships with veterinary clinics and cater towards a significant gap in the market.
2. Theravance Biopharma US, Inc: San Francisco, CA
With a number of clinical programs under its umbrella, Theravance Biopharma works to develop key medicines to improve the lives of patients with long-term conditions.
The company’s ongoing success has seen it open a new corporate office in Dublin, in order to further its presence within Ireland.
"This important expansion within Ireland provides an opportunity to tap into the extensive biopharmaceutical talent pool within the country,” commented President Dr Ann Brady.
“Our Irish team looks forward to helping to build on Theravance Biopharma's legacy of scientific expertise, advance our pipeline of potential therapies in multiple disease areas, and ultimately change the way serious diseases are treated."